Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic?

Neurochemistry International

Volumn 61, Issue 4, 2012, Pages 559-565

  Caraci, Filippo ^a   Battaglia, Giuseppe ^b   Sortino, Maria Angela ^a   Spampinato, Simona ^a   Molinaro, Gemma ^b   Copani, Agata ^a,c   Nicoletti, Ferdinando ^b,d   Bruno, Valeria ^b,d  

^a UNIVERSITY OF CATANIA   (Italy)

^b IRCCS NEUROMED   (Italy)

^c CNR   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Brain ischemia; Chronic neurodegenerative disorders; Metabotropic glutamate receptors; Neurodegeneration; Neuroprotection; Neurotrophic factors

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; LEVODOPA; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; N PHENYL 7 (HYDROXYIMINO)CYCLOPROPA[B]CHROMEN 1A CARBOXAMIDE; NERVE GROWTH FACTOR; NEURITE PROMOTING FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN DAMAGE; BRAIN ISCHEMIA; DOPAMINERGIC NERVE CELL; DYSKINESIA; EXCITOTOXICITY; HUMAN; INTOXICATION; LEARNING DISORDER; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; STROKE;

ALLOSTERIC REGULATION; ANIMALS; HAPLORHINI; MICE; NEUROPROTECTIVE AGENTS; RECEPTORS, METABOTROPIC GLUTAMATE;

MUS;

EID: 84865741390     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.01.017     Document Type: Article

References (122)

1. G.W. Albers, M.P. Goldberg, and D.W. Choi N-methyl-d-aspartate antagonists: ready for clinical trial in brain ischemia? Ann. Neurol. 125 1989 398 403
2. A. Ambrosini, L. Bresciani, S. Fracchia, N. Brunello, and G. Racagni Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-d-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro Mol. Pharmacol. 47 1995 1057 1064
3. M.T. Armentero, R. Fancellu, G. Nappi, P. Bramanti, and F. Blandini Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease Neurobiol. Dis. 22 2006 1 9
4. E. Aronica, M.V. Catania, J. Geurts, B. Yankaya, and D. Troost Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes Neuroscience 105 2001 509 520
5. E. Aronica, J.A. Gorter, H. Ijlst-Keizers, A.J. Rozemuller, B. Yankaya, S. Leenstra, and D. Troost Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins Eur. J. Neurosci. 17 2003 2106 2118
6. S. Attucci, V. Carlà, G. Mannaioni, and F. Moroni Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges Br. J. Pharmacol. 132 2001 799 806
7. R. Balázs, S. Miller, C. Romano, A. de Vries, Y. Chun, and C.W. Cotman Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacological properties and agonist regulation J. Neurochem. 69 1997 151 163
8. G. Battaglia, V. Bruno, R.T. Ngomba, R. Di Grezia, A. Copani, and F. Nicoletti Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death Eur. J. Pharmacol. 356 1998 271 274
9. G. Battaglia, V. Bruno, A. Pisani, D. Centonze, M.V. Catania, P. Calabresi, and F. Nicoletti Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission Mol. Cell. Neurosci. 17 2001 1071 1083
10. G. Battaglia, C.L. Busceti, G. Molinaro, F. Biagioni, M. Storto, F. Fornai, F. Nicoletti, and V. Bruno Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice J. Neurosci. 24 2004 828 835
11. G. Battaglia, C.L. Busceti, G. Molinaro, F. Biagioni, A. Traficante, F. Nicoletti, and V. Bruno Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine J. Neurosci. 26 2006 7222 7229
12. G. Battaglia, G. Molinaro, B. Riozzi, M. Storto, C.L. Busceti, P. Spinsanti, D. Bucci, V. Di Liberto, G. Mudò, C. Corti, M. Corsi, F. Nicoletti, N. Belluardo, and V. Bruno Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons PLoS One 4 8 2009 e6591
13. G. Battaglia, M. Cannella, B. Riozzi, S. Orobello, M.L. Maat-Schieman, E. Aronica, C.L. Busceti, A. Ciarmiello, S. Alberti, E. Amico, J. Sassone, S. Sipione, V. Bruno, L. Frati, F. Nicoletti, and F. Squitieri Early defect of transforming growth factor beta-1 formation in Huntington's disease J. Cell Mol. Med. 15 2010 551 557
14. Battaglia, G.; Riozzi, B.; Molinaro, G.; Bucci, D.; Storto, M.; Pallottino, M.; Nicoletti, F.; and Bruno, V.; 2011. Group-II mGluRs as drug targets in the treatment of amyotrophic lateral sclerosis. Curr. Neuropharmacol. 9(S1), 3.
15. D. Berg, J. Godau, C. Trenkwalder, K. Eggert, I. Csoti, A. Storch, H. Huber, M. Morelli-Canelo, M. Stamelou, V. Ries, M. Wolz, C. Schneider, T. Di Paolo, F. Gasparini, S. Hariry, M. Vandemeulebroecke, W. Abi-Saab, K. Cooke, D. Johns, and B. Gomez-Mancilla AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials Mov. Disord. 26 2011 1243 1250
16. Y.D. Black, D. Xiao, D. Pellegrino, A. Kachroo, A.L. Brownell, and M.A. Schwarzschild Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease Neurosci. Lett. 486 2010 161 165
17. A. Bond, M.J. O'Neill, C.A. Hicks, J.A. Monn, and D. Lodge Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia Neuroreport 9 1998 1191 1193
18. A. Bond, N. Ragumoorthy, J.A. Monn, C.A. Hicks, M.A. Ward, D. Lodge, and M.J. O'Neill LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia Neurosci. Lett. 273 1999 191 194
19. A. Bond, N.M. Jones, C.A. Hicks, G.M. Whiffin, M.A. Ward, M.F. O'Neill, A.E. Kingston, J.A. Monn, P.L. Ornstein, D.D. Schoepp, D. Lodge, and M.J. O'Neill Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo J. Pharmacol. Exp. Ther. 294 2000 800 809
20. P.R. Brakeman, A.A. Lanahan, R. O'Brien, K. Roche, C.A. Barnes, R.L. Huganir, and P.F. Worley Homer: a protein that selectively binds metabotropic glutamate receptors Nature 386 1997 284 288
21. D.P. Brazil, and B.A. Hemmings Ten years of protein kinase B signalling: a hard Akt to follow Trends Biochem. Sci. 26 2001 657 664
22. V. Bruno, A. Copani, G. Battaglia, R. Raffaele, H. Shinozaki, and F. Nicoletti Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death Eur. J. Pharmacol. 256 1994 109 112
23. V. Bruno, G. Battaglia, A. Copani, R.G. Giffard, G. Raciti, R. Raffaele, H. Shinozaki, and F. Nicoletti Activation of class II or class III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration Eur. J. Neurosci. 7 1995 1906 1913
24. V. Bruno, A. Copani, L. Bonanno, T. Knoepfel, R. Kuhn, P.J. Roberts, and F. Nicoletti Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures Eur. J. Pharmacol. 310 1996 61 66
25. V. Bruno, F.X. Sureda, M. Storto, G. Casabona, A. Caruso, T. Knopfel, R. Kuhn, and F. Nicoletti The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling J. Neurosci. 17 1997 1891 1897
26. V. Bruno, G. Battaglia, A. Copani, G. Casabona, M. Storto, V. Di Giorgi Gerevini, R. Ngomba, and F. Nicoletti Metabotropic glutamate receptors and neurodegeneration Prog. Brain Res. 116 1998 209 221
27. V. Bruno, G. Battaglia, G. Casabona, A. Copani, F. Caciagli, and F. Nicoletti Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta J. Neurosci. 18 1998 9594 9600
28. V. Bruno, G. Battaglia, I. Ksiazek, H. van der Putten, M.V. Catania, R. Giuffrida, S. Lukic, T. Leonhardt, W. Inderbitzin, F. Gasparini, R. Kuhn, D.R. Hampson, F. Nicoletti, and P.J. Flor Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death J. Neurosci. 20 2000 6413 6420
29. V. Bruno, G. Battaglia, A. Copani, M. D'Onofrio, P. Di Iorio, A. De Blasi, D. Melchiorri, P.J. Flor, and F. Nicoletti Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs J. Cereb. Blood Flow Metab. 21 2001 1013 1033
30. A. Buisson, and D.W. Choi The inhibitory mGluR agonist, S-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death Neuropharmacology 34 1995 1081 1087
31. F. Caraci, G. Molinaro, G. Battaglia, M.L. Giuffrida, B. Riozzi, A. Traficante, V. Bruno, M. Cannella, S. Merlo, X. Wang, B.A. Heinz, E.S. Nisenbaum, T.C. Britton, F. Drago, M.A. Sortino, A. Copani, and F. Nicoletti Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective Mol. Pharmacol. 79 2011 618 626
32. F. Caraci, S. Spampinato, M.A. Sortino, P. Bosco, G. Battaglia, V. Bruno, F. Drago, F. Nicoletti, and A. Copani Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection Cell Tissue Res. 2011 10.1007/s00441-011-1230-6
33. Caraci, F.; Bosco, P.; Signorelli, M.; Spada, R.S.; Cosentino, F.I.; Toscano, G.; Bonforte, C.; Muratore, S.; Prestianni, G.; Panerai, S.; Giambirtone, M.C.; Gulotta, E.; Romano, C.; Salluzzo, M.G.; Nicoletti, F.; Copani, A.; Drago, F.; Aguglia, E.; Ferri, R.; 2011c. The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression. Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2011.08.006.
34. D.W. Choi Glutamate neurotoxicity and diseases of the nervous system Neuron 1 1988 623 634
35. D.W. Choi Glutamate receptors and the induction of excitotoxic neuronal death Prog. Brain Res. 100 1994 47 51
36. R. Ciccarelli, P. Di Iorio, V. Bruno, G. Battaglia, I. D'Alimonte, M. D'Onofrio, F. Nicoletti, and F. Caciagli Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes Glia 27 1999 275 281
37. A. Cippitelli, R. Damadzic, K. Frankola, A. Goldstein, A. Thorsell, E. Singley, R.L. Eskay, and M. Heilig Alcohol-induced neurodegeneration, suppression of transforming growth factor-beta, and cognitive impairment in rats: prevention by group II metabotropic glutamate receptor activation Biol. Psychiatry 67 2010 823 830
38. P.J. Conn, G. Battaglia, M.J. Marino, and F. Nicoletti Metabotropic glutamate receptors in the basal ganglia motor circuit Nat. Rev. Neurosci. 6 2005 787 798
39. A. Copani, V. Bruno, G. Battaglia, G. Leanza, R. Pellitteri, A. Russo, S. Stanzani, and F. Nicoletti Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide Mol. Pharmacol. 47 1995 890 897
40. A. Copani, S. Guccione, L. Giurato, F. Caraci, M. Calafiore, M.A. Sortino, and F. Nicoletti The cell cycle molecules behind neurodegeneration in Alzheimer's disease: perspectives for drug development Curr. Med. Chem. 15 2008 2420 2432
41. C. Corti, G. Battaglia, G. Molinaro, B. Riozzi, A. Pittaluga, M. Corsi, M. Mugnaini, F. Nicoletti, and V. Bruno The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection J. Neurosci. 27 2007 8297 8308
42. A. Cozzi, E. Meli, V. Carlà, R. Pellicciari, F. Moroni, and D.E. Pellegrini-Giampietro Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology 43 2002 119 130
43. S. D'Antoni, A. Berretta, G. Seminara, P. Longone, A.M. Giuffrida-Stella, G. Battaglia, M.A. Sortino, F. Nicoletti, and M.V. Catania A prolonged pharmacological blockade of type-5 metabotropic glutamate receptors protects cultured spinal cord motor neurons against excitotoxic death Neurobiol. Dis. 42 2011 252 264
44. J. De Vry, E. Horváth, and R. Schreiber Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620 Eur. J. Pharmacol. 428 2001 203 214
45. V. Di Liberto, A. Bonomo, M. Frinchi, N. Belluardo, and G. Mudò Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain Neuroscience 165 2010 863 873
46. A.J. Doherty, M.J. Palmer, J.M. Henley, G.L. Collingridge, and D.E. Jane (RS)-2-Chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus Neuropharmacology 36 1997 265 267
47. M. D'Onofrio, L. Cuomo, G. Battaglia, R.T. Ngomba, M. Storto, A.E. Kingston, F. Orzi, A. De Blasi, P. Di Iorio, F. Nicoletti, and V. Bruno Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways J. Neurochem. 78 2001 435 445
48. S. Duty Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease Br. J. Pharmacol. 161 2010 271 287
49. A.C. Emery, S. Pshenichkin, G.R. Takoudjou, E. Grajkowska, B.B. Wolfe, and J.T. Wroblewski The Protective Signaling of Metabotropic Glutamate Receptor 1 Is Mediated by Sustained, β-Arrestin-1-dependent ERK Phosphorylation J. Biol. Chem. 285 2010 26041 26048
50. Emery, A.C.; Hathaway, H.; Pshenichkin, S.; Takoudjou, G.R.; Diraddo, J.; Grajkowska, E.; Yasuda, R.P.; Wolfe, B.B. and Wroblewski, J.T.; 2011. Ligand bias at mGlu1 receptors reveals a second binding site at new endogenous agonists. Curr. Neuropharmacol. 9(S1), 18.
51. D.W. Engers, J.R. Field, U. Le, Y. Zhou, J.D. Bolinger, R. Zamorano, A.L. Blobaum, C.K. Jones, S. Jadhav, C.D. Weaver, P.J. Conn, C.W. Lindsley, C.M. Niswender, and C.R. Hopkins Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats J. Med. Chem. 54 2011 1106 1110
52. F. Ferraguti, and R. Shigemoto Metabotropic glutamate receptors Cell Tissue Res. 326 2006 483 504
53. F. Gasparini, V. Bruno, G. Battaglia, S. Lukic, T. Leonhardt, W. Inderbitzin, D. Laurie, B. Sommer, M.A. Varney, S.D. Hess, E.C. Johnson, R. Kuhn, S. Urwyler, D. Sauer, C. Portet, M. Schmutz, F. Nicoletti, and P.J. Flor (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo J. Pharmacol. Exp. Ther. 289 1999 1678 1687
54. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. Brooks, C.N. Svendsen, and P. Heywood Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat. Med. 9 2003 589 595
55. G.E. Hardingham, and H. Bading Synaptic versus extra synaptic NMDA receptor signalling: implications for neurodegenerative disorders Nat. Rev. Neurosci. 11 2010 682 696
56. P. Henrich-Noack, C.D. Hatton, and K.G. Reymann The mGlu receptor ligand (S)-4C3HPG protects neurons after global ischaemia in gerbils Neuroreport 9 1998 985 988
57. P. Henrich-Noack, P.J. Flor, C.F. Sabelhaus, K. Prass, U. Dirnagl, F. Gasparini, A. Sauter, M. Rudin, and K.G. Reymann Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage Neuropharmacology 39 2000 911 917
58. I. Herrero, M.T. Miras-Portugal, and J. Sánchez-Prieto Functional switch from facilitation to inhibition in the control of glutamate release by metabotropic glutamate receptors J. Biol. Chem. 273 1998 1951 1958
59. L.L. Jantzie, D.M. Talos, D.B. Selip, L. An, M.C. Jackson, R.D. Folkerth, W. Deng, and F.E. Jensen Developmental regulation of group I metabotropic glutamate receptors in the premature brain and their protective role in a rodent model of periventricular leukomalacia Neuron Glia Biol. 14 2011 1 12
60. A.E. Kingston, M.J. O'Neill, A. Bond, V. Bruno, G. Battaglia, F. Nicoletti, J.R. Harris, B.P. Clark, J.A. Monn, D. Lodge, and D.D. Schoepp Neuroprotective action of novel and potent ligands of group-I and group-II metabotropic glutamate receptors Ann. NY Acad. Sci. 890 1999 438 439
61. A.E. Kingston, M.J. O'Neill, A. Lam, K.R. Bales, J.A. Monn, and D.D. Schoepp Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795 Eur. J. Pharmacol. 377 1999 155 165
62. B.J. Kinon, L. Zhang, B.A. Millen, O.O. Osuntokun, J.E. Williams, S. Kollack-Walker, K. Jackson, L. Kryzhanovskaya, N. Jarkova the HBBI Study Group A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia J. Clin. Psychopharmacol. 31 2011 349 355
63. A. Kohara, M. Takahashi, S. Yatsugi, S. Tamura, Y. Shitaka, S. Hayashibe, S. Kawabata, and M. Okada Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models Brain Res. 1191 2008 168 179
64. M. Koller, and S. Urwyler Novel N-methyl-d-aspartate receptor antagonists: a review of compounds patented since 2006 Exp. Opin. Ther. Pat. 20 2010 1683 1702
65. S.J. Koo, and S.L. Pfaff Fine-tuning motor neuron properties: signaling from the periphery Neuron 35 2002 823 826
66. A.G. Lam, M.A. Soriano, J.A. Monn, D.D. Schoepp, D. Lodge, and J. McCulloch Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia Neurosci. Lett. 254 1998 121 123
67. E. Landucci, F. Boscia, E. Gerace, T. Scartabelli, A. Cozzi, F. Moroni, G. Mannaioni, and D.E. Pellegrini-Giampietro Involvement of endocannabinoid signaling in the neuroprotective effects of subtype 1 metabotropic glutamate receptor antagonists in models of cerebral ischemia Int. Rev. Neurobiol. 85 2009 337 350
68. E. Landucci, T. Scartabelli, E. Gerace, F. Moroni, and D.E. Pellegrini-Giampietro CB1 receptors and post-ischemic brain damage: studies on the toxic and neuroprotective effects of cannabinoids in rat organotypic hippocampal slices Neuropharmacology 60 2011 674 682
69. L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, and F. Collins GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 1993 1130 1132
70. P. Lipton Ischemic cell death in brain neurons Physiol. Rev. 79 1999 1431 1568
71. S.A. Lipton Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond Nat. Rev. Drug Discov. 5 2006 160 170
72. D.T. Loo, A. Copani, C.J. Pike, E.R. Whittemore, A.J. Walencewicz, and C.W. Cotman Apoptosis is induced by beta-amyloid in cultured central nervous system neurons Proc. Natl. Acad. Sci. USA 90 1993 7951 7955
73. M. Maj, V. Bruno, Z. Dragic, R. Yamamoto, G. Battaglia, W. Inderbitzin, N. Stoehr, T. Stein, F. Gasparini, I. Vranesic, R. Kuhn, F. Nicoletti, and P.J. Flor (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection Neuropharmacology. 45 2003 895 906
74. D. Makarewicz, M. Duszczyk, R. Gadamski, W. Danysz, and J.W. Łazarewicz Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models Neurochem. Int. 48 2006 485 490
75. G. Mannaioni, M.J. Marino, O. Valenti, S.F. Traynelis, and P.J. Conn Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function J. Neurosci. 21 2001 5925 5934
76. M.J. Marino, D.L. Williams Jr, J.A. O'Brien, O. Valenti, T.P. McDonald, M.K. Clements, R. Wang, A.G. DiLella, J.F. Hess, G.G. Kinney, and P.J. Conn Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment Proc. Natl. Acad. Sci. USA 100 2003 13668 13673
77. G.J. Masilamoni, J.W. Bogenpohl, D. Alagille, K. Delevich, G. Tamagnan, J.R. Votaw, T. Wichmann, and Y. Smith Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys Brain 134 2011 2057 2073
78. B. Meldrum Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission Cerebrovasc. Brain Metab. Rev. 2 1990 27 57
79. E. Meli, R. Picca, S. Attucci, A. Cozzi, F. Peruginelli, F. Moroni, and D.E. Pellegrini-Giampietro Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to postischemic neuronal injury in vitro and in vivo Pharmacol. Biochem. Behav. 73 2002 439 446
80. P.G. Mermelstein Membrane-localised oestrogen receptor alpha and beta influence neuronal activity through activation of metabotropic glutamate receptors J. Neuroendocrinol. 21 2009 257 262
81. P.E. Micevych, and P.G. Mermelstein Membrane estrogen receptors acting through metabotropic glutamate receptors: an emerging mechanism of estrogen action in brain Mol. Neurobiol. 38 2008 66 77
82. S. Miller, C. Romano, and C.W. Cotman Growth factor upregulation of a phosphoinositide-coupled metabotropic glutamate receptor in cortical astrocytes J. Neurosci. 15 1995 6103 6109
83. S. Miller, N. Sehati, C. Romano, and C.W. Cotman Exposure of astrocytes to thrombin reduces levels of the metabotropic glutamate receptor mGluR5 J. Neurochem. 67 1996 1435 1447
84. F. Moroni, S. Attucci, A. Cozzi, E. Meli, R. Picca, M.A. Scheideler, R. Pellicciari, C. Noe, I. Sarichelou, and D.E. Pellegrini-Giampietro The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death Neuropharmacology 42 2002 741 751
85. S.G. Moyanova, F. Mastroiacovo, L.V. Kortenska, R.G. Mitreva, E. Fardone, I. Santolini, M. Sobrado, G. Battaglia, V. Bruno, F. Nicoletti, and R.T. Ngomba Protective role for type 4 metabotropic glutamate receptors against ischemic brain damage J. Cereb. Blood Flow Metab. 31 2011 1107 1118
86. K. Murotomi, N. Takagi, G. Takayanagi, M. Ono, S. Takeo, and K. Tanonaka MGluR1 antagonist decreases tyrosine phosphorylation of NMDA receptor and attenuates infarct size after transient focal cerebral ischemia J. Neurochem. 105 2008 1625 1634
87. K. Murotomi, N. Takagi, R. Mizutani, T.A. Honda, M. Ono, S. Takeo, and K. Tanonaka MGluR1 antagonist decreased NADPH oxidase activity and superoxide production after transient focal cerebral ischemia J. Neurochem. 114 2010 1711 1719
88. F. Nicoletti, V. Bruno, M.V. Catania, G. Battaglia, A. Copani, G. Barbagallo, V. Ceña, J. Sanchez-Prieto, P.F. Spano, and M. Pizzi Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection Neuropharmacology 38 1999 1477 1484
89. F. Nicoletti, J. Bockaert, G.L. Collingridge, P.J. Conn, F. Ferraguti, D.D. Schoepp, J.T. Wroblewski, and J.P. Pin Metabotropic glutamate receptors: from the workbench to the bedside 2011 Neuropharmacology 60 2011 1017 1041
90. C.M. Niswender, K.A. Johnson, C.D. Weaver, C.K. Jones, Z. Xiang, Q. Luo, A.L. Rodriguez, J.E. Marlo, T. de Paulis, A.D. Thompson, E.L. Days, T. Nalywajko, C.A. Austin, M.B. Williams, J.E. Ayala, R. Williams, C.W. Lindsley, and P.J. Conn Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 Mol. Pharmacol. 74 2008 1345 1358
91. C.M. Niswender, and P.J. Conn Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu. Rev. Pharmacol. Toxicol. 50 2010 295 322
92. J.W. Olney The toxic effects of glutamate and related compounds in the retina and the brain Retina 2 1982 341 359
93. J.W. Olney, D.F. Wozniak, and N.B. Farber Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies Arch. Neurol. 54 1997 1234 1240
94. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat. Med. 13 2007 1102 1107
95. D.E. Pellegrini-Giampietro The distinct role of mGlu1 receptors in post-ischemic neuronal death Trends Pharmacol. Sci. 24 2003 461 470
96. A. Pisani, P. Gubellini, P. Bonsi, F. Conquet, B. Picconi, D. Centonze, G. Bernardi, and P. Calabresi Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons Neuroscience 106 2001 579 587
97. D.L. Price, E. Rockenstein, K. Ubhi, V. Phung, N. MacLean-Lewis, D. Askay, A. Cartier, B. Spencer, C. Patrick, P. Desplats, M.H. Ellisman, and E. Masliah Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy-implications for excitotoxicity PLoS One 5 2010 e14020
98. S. Pshenichkin, M. Dolińska, M. Klauzińska, V. Luchenko, E. Grajkowska, and J.T. Wroblewski Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation - possible role as a dependence receptor Neuropharmacology 55 2008 500 508
99. Pshenichkin, S.; Emery, A.C.; Takoudjou, G.R.; Diraddo, J.; Hathaway, H.; Grajkowska, E.; Wroblewski, J.T.; 2011. Neuroprotective and neurotoxic signaling of mGlu1 receptors. Current Neuropharmacology. 9(S1), 54.
100. R. Rong, J.Y. Ahn, H. Huang, E. Nagata, D. Kalman, J.A. Kapp, J. Tu, P.F. Worley, S.H. Snyder, and K. Ye PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis Nat. Neurosci. 6 2003 1153 1161
101. D. Rossi, L. Brambilla, C.F. Valori, C. Roncoroni, A. Crugnola, T. Yokota, D.E. Bredesen, and A. Volterra Focal degeneration of astrocytes in amyotrophic lateral sclerosis Cell Death Differ. 15 2008 1691 1700
102. S.M. Rothman, and J.W. Olney Glutamate and the pathophysiology of hypoxic-ischemic brain damage Ann. Neurol. 19 1986 105 111
103. Rothstein, J.D.; 1995-1996. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin. Neurosci. 3, 348-359.
104. T. Scartabelli, E. Gerace, E. Landucci, F. Moroni, and D.E. Pellegrini-Giampietro Neuroprotection by group I mGlu receptors in a rat hippocampal slice model of cerebral ischemia is associated with the PI3K-Akt signaling pathway: a novel postconditioning strategy? Neuropharmacology 55 2008 509 516
105. Scartabelli, T.; Gerace, E.; Landucci, E.; Moroni, F. and Pellegrini-Giampietro, D.E.; 2011. Neuroprotection following postconditioning via group I mGlu receptor activation is coupled to the PI3K/Akt/GSK3β signaling pathway in a rat organotypic hippocampal slice model of cerebral ischemia. Curr. Neuropharmacol. 9(S1), 57.
106. A. Schober, H. Peterziel, C.S. von Bartheld, H. Simon, K. Krieglstein, and K. Unsicker GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action Neurobiol. Dis. 25 2007 378 391
107. D.D. Schoepp, D.E. Jane, and J.A. Monn Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38 1999 1431 1476
108. B.K. Siesjö, K. Katsura, and T. Kristián The biochemical basis of cerebral ischemic damage J. Neurosurg. Anesthesiol. 7 1995 47 52
109. J.T. Slevin, G.A. Gerhardt, C.D. Smith, D.M. Gash, R. Kryscio, and B. Young Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor J. Neurosurg. 102 2005 216 222
110. S.F. Spampinato, G. Molinaro, S. Merlo, L. Iacovelli, F. Caraci, G. Battaglia, F. Nicoletti, V. Bruno, and M.A. Sortino Estrogen receptors and type-1 metabotropic glutamate receptors are interdependent in protecting cortical Neurons against {beta}-amyloid toxicity Mol. Pharmacol. 81 2012 12 20
111. D.L. Taylor, L.T. Diemel, and J.M. Pocock Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity J. Neurosci. 23 2003 2150 2160
112. I. Tesseur, K. Zou, L. Esposito, F. Bard, E. Berber, J.V. Can, A.H. Lin, L. Crews, P. Tremblay, P. Mathews, L. Mucke, E. Masliah, and T. Wyss-Coray Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology J. Clin. Invest. 116 2006 3060 3069
113. A.G. Thomas, W. Liu, J.L. Olkowski, Z. Tang, Q. Lin, X.C. Lu, and B.S. Slusher Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta Eur. J. Pharmacol. 430 2001 33 40
114. C. Thomsen, V. Bruno, F. Nicoletti, M. Marinozzi, and R. Pellicciari (2S,1′S,2′S,3′R)-2-(2′-Carboxy-3′- phenylcyclopropyl)glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors Mol. Pharmacol. 50 1996 6 9
115. J.C. Tu, B. Xiao, J.P. Yuan, A.A. Lanahan, K. Leoffert, M. Li, D.J. Linden, and P.F. Worley Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors Neuron 21 1998 717 726
116. J.C. Tu, B. Xiao, S. Naisbitt, J.P. Yuan, R.S. Petralia, P. Brakeman, A. Doan, V.K. Aakalu, A.A. Lanahan, M. Sheng, and P.F. Worley Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins Neuron 23 1999 583 592
117. O. Valenti, M.J. Marino, M. Wittmann, E. Lis, A.G. DiLella, G.G. Kinney, and P.J. Conn Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse J. Neurosci. 23 2003 7218 7226
118. C.G. Werner, T. Scartabelli, T. Pancani, E. Landucci, F. Moroni, and D.E. Pellegrini-Giampietro Differential role of mGlu1 and mGlu5 receptors in rat hippocampal slice models of ischemic tolerance Eur. J. Neurosci. 25 2007 3597 3604
119. W. Xu, T.P. Wong, N. Chery, T. Gaertner, Y.T. Wang, and M. Baudry Calpain-mediated mGluR1alpha truncation: a key step in excitotoxicity Neuron 53 2007 399 412
120. H. Yoshioka, M. Sugita, and H. Kinouchi Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia Neurosci. Lett. 461 2009 266 270
121. M. Zhou, W. Xu, G. Liao, X. Bi, and M. Baudry Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1alpha truncation Exp. Neurol. 218 2009 75 82
122. G.J. Zipfel, J.M. Lee, and D.W. Choi Reducing calcium overload in the ischemic brain N. Engl. J Med. 341 1999 1543 1544